Clinical trial
Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease: A Randomized, Double-Blind, Sham-Controlled Clinical Trial
NCT07891650 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease: A Randomized, Double-Blind, Sham-Controlled Clinical Trial
- Lead sponsor
- Xuanwu Hospital, Beijing
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2027
- Enrollment
- 160 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
cerebral small vessel disease, vascular cognitive impairment
Arms
As registered; 2 arms.
-
Active Personalized Intermittent Theta Burst Stimulation
Participants will receive active personalized intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex, with the target individualized using resting-state functional MRI and neuronavigation. Treatment will last 24 weeks: four sessions per day for five consecutive days in week 1, followed by four sessions on one treatment day each week during weeks 2-24. Each session will deliver 1,800 pulses at 80-100% of the resting motor threshold, adjusted according to tolerability, with 50-60 minutes between sessions.
-
Sham Personalized Intermittent Theta Burst Stimulation
Participants will receive sham stimulation at the individualized left dorsolateral prefrontal cortex target using a dedicated sham coil or sham mode. Sham stimulation will mimic the sounds, vibration, and procedures of active treatment without delivering effective magnetic stimulation. The schedule will match the active group: four sessions per day for five consecutive days in week 1, followed by four sessions on one treatment day each week during weeks 2-24, with 50-60 minutes between sessions.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 24
The Montreal Cognitive Assessment (MoCA) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Change will be calculated as the week 24 total score minus the baseline total score. A positive change indicates improvement.
Lead sponsor's other trials
Xuanwu Hospital, Beijing, most recent start first.
+358 more trials See the organization page
Similar trials
Same condition (Cerebral Small Vessel Diseases) and phase, most recent start first.
+37 more trials See the condition page